Vaxcyte, Inc.

Сильный индекс, значительно упал. Оптимистичный взгляд на свои позиции резко сменился на неуверенность.

Strong index, significantly down. An optimistic view of his position suddenly changed to uncertainty.

Сильный индекс, без изменений. Рынок не поддерживает быков.

Strong index, flat. The market does not support the bulls.

Средний индекс, незначительно вырос. Отток средств из лонгов на высоком уровне.

Medium index, slightly up. Outflow of funds from longs at a high level.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 124,149 contracts has been traded thus far today, a contract volume which is representative of approximately 12.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 151.6% of UNH's average daily trading volume over the past month, of 8.2 million shares. Especially high volume was seen for the $400 strike call option expiring May 15, 2026, with 10,664 contracts trading so far today, representing approximately 1.1 million underlying shares of UNH. Below is a chart showing UNH's trailing twelve month trading history, with the $400 strike highlighted in orange:
MongoDB Inc (Symbol: MDB) options are showing a volume of 21,608 contracts thus far today. That number of contracts represents approximately 2.2 million underlying shares, working out to a sizeable 139.5% of MDB's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $177.50 strike put option expiring May 22, 2026, with 1,830 contracts trading so far today, representing approximately 183,000 underlying shares of MDB. Below is a chart showing MDB's trailing twelve month trading history, with the $177.50 strike highlighted in orange:
And Vaxcyte Inc (Symbol: PCVX) saw options trading volume of 19,518 contracts, representing approximately 2.0 million underlying shares or approximately 136.2% of PCVX's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $50 strike put option expiring October 16, 2026, with 5,446 contracts trading so far today, representing approximately 544,600 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $50 strike highlighted in orange:
For the various different available expirations for UNH options, MDB options, or PCVX options, visit StockOptionsChannel.com.
Also see:
Steven Cohen Stock Picks
ZIPR Videos
YTD Return on Dow
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Tuesday Option Activity: UNH, MDB, PCVX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vaxcyte Inc (Symbol: PCVX), where a total volume of 10,776 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 76.3% of PCVX's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $45 strike put option expiring October 16, 2026, with 3,067 contracts trading so far today, representing approximately 306,700 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $45 strike highlighted in orange:
Marvell Technology Inc (Symbol: MRVL) saw options trading volume of 160,810 contracts, representing approximately 16.1 million underlying shares or approximately 72% of MRVL's average daily trading volume over the past month, of 22.3 million shares. Particularly high volume was seen for the $100 strike call option expiring March 27, 2026, with 34,867 contracts trading so far today, representing approximately 3.5 million underlying shares of MRVL. Below is a chart showing MRVL's trailing twelve month trading history, with the $100 strike highlighted in orange:
And Corcept Therapeutics Inc (Symbol: CORT) options are showing a volume of 10,145 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 71.8% of CORT's average daily trading volume over the past month, of 1.4 million shares. Especially high volume was seen for the $50 strike call option expiring April 17, 2026, with 2,322 contracts trading so far today, representing approximately 232,200 underlying shares of CORT. Below is a chart showing CORT's trailing twelve month trading history, with the $50 strike highlighted in orange:
For the various different available expirations for PCVX options, MRVL options, or CORT options, visit StockOptionsChannel.com.
Also see:
Chase Coleman Stock Picks
CVGW market cap history
Semiconductors Dividend Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Wednesday Option Activity: PCVX, MRVL, CORT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Crane Co (Symbol: CR), where a total of 3,621 contracts have traded so far, representing approximately 362,100 underlying shares. That amounts to about 96.2% of CR's average daily trading volume over the past month of 376,265 shares. Particularly high volume was seen for the $180 strike put option expiring April 17, 2026, with 1,500 contracts trading so far today, representing approximately 150,000 underlying shares of CR. Below is a chart showing CR's trailing twelve month trading history, with the $180 strike highlighted in orange:
Vaxcyte Inc (Symbol: PCVX) options are showing a volume of 11,180 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 88.9% of PCVX's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $45 strike put option expiring October 16, 2026, with 3,750 contracts trading so far today, representing approximately 375,000 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $45 strike highlighted in orange:
And Piper Sandler Companies (Symbol: PIPR) options are showing a volume of 1,647 contracts thus far today. That number of contracts represents approximately 164,700 underlying shares, working out to a sizeable 81% of PIPR's average daily trading volume over the past month, of 203,395 shares. Particularly high volume was seen for the $265 strike call option expiring September 18, 2026, with 820 contracts trading so far today, representing approximately 82,000 underlying shares of PIPR. Below is a chart showing PIPR's trailing twelve month trading history, with the $265 strike highlighted in orange:
For the various different available expirations for CR options, PCVX options, or PIPR options, visit StockOptionsChannel.com.
Also see:
Barry Rosenstein Stock Picks
Funds Holding VEEV
Consumer Stocks Hedge Funds Are Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Monday Option Activity: CR, PCVX, PIPR

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $244.9 million dollar outflow -- that's a 3.0% decrease week over week (from 65,450,000 to 63,475,000). Among the largest underlying components of XBI, in trading today Moderna Inc (Symbol: MRNA) is up about 2.3%, Vaxcyte Inc (Symbol: PCVX) is up about 1%, and Roivant Sciences Ltd (Symbol: ROIV) is up by about 0.9%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $132.09 as the 52 week high point — that compares with a last trade of $123.77. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
STG Average Annual Return
PHT Insider Buying
Top Ten Hedge Funds Holding PBCT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XBI, MRNA, PCVX, ROIV: ETF Outflow Alert

(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, reported its fourth-quarter and full-year 2025 financial results and provided a business update.
The company's lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate currently in a Phase 3 adult clinical program and a Phase 2 infant study. VAX-31 is designed to provide the broadest serotype coverage of any PCV in clinical development, aiming to prevent invasive pneumococcal disease (IPD) and pneumonia. The FDA has granted Breakthrough Therapy Designation for VAX-31 in adults.
In adults, three pivotal Phase 3 trials (OPUS-1, OPUS-2, and OPUS-3) are underway, enrolling thousands of participants to evaluate safety, tolerability, and immunogenicity compared to current standards of care, Prevnar 20 and Capvaxine. Topline data from OPUS-1 is expected in the fourth quarter of 2026, while readouts from OPUS-2 and OPUS-3 are anticipated in the first half of 2027.
In infants, enrolment has been completed in a Phase 2 dose-finding study, with topline data expected in the first half of 2027.
Beyond VAX-31, Vaxcyte is advancing:
•VAX-24, a 24-valent PCV candidate for infants, currently in Phase 2 clinical development, designed to cover more serotypes than any marketed infant PCV.
•VAX-XL, a third-generation PCV in early development, leveraging carrier-sparing conjugation technology to further expand coverage.
•VAX-A1, a novel vaccine candidate for Group A Strep, with a Phase 1 adult study planned for 2026.
•VAX-GI, a preclinical vaccine candidate targeting Shigella infections.
The company ended December 31, 2025, with cash, cash equivalents and investments of $2.4 billion.
For Q4 2025, net loss was $246.5 million, compared to $137.1 million in the year ago quarter. For the full year net loss widened to $766.6 million compared to $463.9 million from the prior year.
In Q4 2025, Vaxcyte incurred an additional $21.8 million in capital and facility buildout expenditures related to the construction of its dedicated Lonza manufacturing facility. By year-end, total expenditures reached $335.4 million, with the buildout completed in Q1 2026 within the original projected budget of up to $350 million. This facility is intended to support the potential global commercialization of the company's PCV program.
PCVX has traded between $27.66 and $83.33 over the past year. The stock closed Tuesday's session at $61.35, up 1.81%. In overnight trading Wednesday, the stock is down 2.97% at $59.53.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte Advances Adult 31-Valent Pneumococcal Phase 3 Trials, Completes Infant Phase 2 Enrollment

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $859.9 million dollar inflow -- that's a 11.1% increase week over week in outstanding units (from 62,850,000 to 69,850,000). Among the largest underlying components of XBI, in trading today Roivant Sciences Ltd (Symbol: ROIV) is up about 1.6%, Halozyme Therapeutics Inc (Symbol: HALO) is up about 1%, and Vaxcyte Inc (Symbol: PCVX) is lower by about 1.6%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $132.09 as the 52 week high point — that compares with a last trade of $122.99. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Preferred Stock Ex-Dividend Calendar
Funds Holding TDY
DVYL Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XBI, ROIV, HALO, PCVX: Large Inflows Detected at ETF

(RTTNews) - Vaxcyte, Inc. (PCVX), a clinical-stage vaccine innovation company, announced that the first participants have been dosed in the OPUS-3 Phase 3 trial evaluating VAX-31, its next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, in adults who have previously received lower-valency pneumococcal vaccines.
Pneumococcal disease, caused by Streptococcus pneumoniae, remains a major public health challenge, leading to invasive infections such as meningitis and bacteremia, as well as pneumonia and otitis media. In the United States alone, pneumococcal pneumonia is estimated to result in about 225,000 adult hospitalizations annually, with drug-resistant strains posing a serious threat.
The OPUS-3 study is a randomized, double-blind, active-controlled trial enrolling approximately 720 adults aged 50 and older across 30 U.S. sites. Participants with prior vaccination histories (PPSV23, PCV20, or other licensed pneumococcal vaccines) will be randomized to receive either VAX-31 or PCV20.
The trial will assess safety, tolerability, and immunogenicity, including whether VAX-31 can boost serotype-specific immune responses in previously vaccinated adults.
Vaxcyte's broader Phase 3 adult program for VAX-31 includes:
•OPUS-1, a pivotal noninferiority trial in pneumococcal-naïve adults, with topline data expected in fourth quarter of 2026.
•OPUS-2, evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine, with topline data anticipated in the first half of 2027.
•OPUS-3, now underway in previously vaccinated adults, with topline data also expected in the first half of 2027.
VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in U.S. adults aged 50+, potentially providing 14-34% broader IPD coverage and 19-31% broader pneumonia coverage compared to current standard-of-care vaccines. The program, finalized in consultation with the FDA, is intended to support a planned Biologics License Application (BLA).
PCVX has traded between $27.66 and $86.44 over the past year. The stock closed Wednesday's trading at $55.35, up 0.67% and rose further in the pre-market to $55.40, up 0.09%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte Doses First Participants In OPUS-3 Phase 3 Trial

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $283.7 million dollar outflow -- that's a 3.5% decrease week over week (from 67,750,000 to 65,400,000). Among the largest underlying components of XBI, in trading today Vaxcyte Inc (Symbol: PCVX) is up about 1.8%, Mirum Pharmaceuticals Inc (Symbol: MIRM) is up about 0.5%, and Revolution Medicines Inc (Symbol: RVMD) is up by about 1.2%. For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average:
Looking at the chart above, XBI's low point in its 52 week range is $66.66 per share, with $132.09 as the 52 week high point — that compares with a last trade of $123.33. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Institutional Holders of RCC
HTHT shares outstanding history
FIIG Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

XBI, PCVX, MIRM, RVMD: Large Outflows Detected at ETF

Key Points
The CTO sold 9,743 shares.
The sale represented 28.9% of Dhaliwal's holdings.
Chief Technical Ops Officer Sells 9,743 Shares
Focused on next-generation vaccines for bacterial diseases, this biotech just reported a notable insider sale amid a challenging year.
Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte (NASDAQ:PCVX), disposed of 9,743 shares in an open-market sale valued at approximately $454,891 according to the SEC Form 4 filing.
Transaction summary
Shares sold (direct)
9,743
Transaction value
~$454,890.93
Post-transaction shares (direct)
23,928
Post-transaction value (direct ownership)
~$1,111,694.88
Transaction value based on SEC Form 4 weighted average purchase price ($46.69); post-transaction value based on Jan. 2 market close ($46.46).
Key questions
How significant was this sale in relation to Dhaliwal's prior holdings?
The transaction reduced direct ownership by 28.9%, shifting Dhaliwal's stake from 33,671 shares to 23,928 shares, with no remaining indirect exposure.
Were any derivative, trust, or administrative mechanisms involved?
This was a straightforward open-market sale of common stock with no derivative exercise, trust, or administrative withholdings reported in the filing.
Company overview
Price (as of market close Jan. 2, 2026)
$46.46
Market capitalization
$6.08 billion
Net income (TTM)
-$657.20 million
1-year price change
-44.20%
* 1-year performance calculated using Jan. 2 as the reference date.
Company snapshot
Vaxcyte is a clinical-stage biotechnology company specializing in the development of next-generation protein vaccines to address unmet medical needs in bacterial infectious disease prevention. With a pipeline led by VAX-24, the company leverages advanced conjugation and protein engineering technologies to expand vaccine coverage and address antibiotic resistance. The strategy centers on innovation in vaccine design and a focus on diseases with significant global health impact, positioning it as a differentiated player in the vaccine development landscape.
Develops clinical-stage vaccines, including VAX-24 for pneumococcal disease, VAX-XP for emerging strains, VAX-A1 for Group A Strep, and VAX-PG for periodontitis.
Operates a biotechnology business model focused on research, development, and eventual commercialization of novel protein-based vaccines targeting bacterial infectious diseases.
Targets healthcare providers, hospitals, and public health agencies seeking advanced vaccine solutions for infectious disease prevention.
What this transaction means for investors
Harpreet Dhaliwal sold a significant portion of his holdings on Dec. 31. The 9,743 share sale represented 28.9% of his holdings.
The transaction comes after a challenging year. The stock price sagged 44.2% over the last year through Jan. 2, while the S&P 500 index returned 18.4% during this period.
Notably, Vaxcyte's shares experienced a sharp drop in late March and early April before modestly recovering. Dhaliwal's transaction could indicate a lack of confidence that the stock price will sustain this momentum.
Vaxcyte doesn't have any approved products in the market, and hence, doesn't produce any revenue. The company lost $520.1 million during the first nine months of 2025.
Monitoring the progress in the approval process will provide a key indicator of the company's success. While you're doing that, following insider transactions can provide clues into directors' and officers' confidence in gaining product approvals.
Glossary
Open-market sale: The sale of securities on a public exchange at prevailing market prices, not through private arrangements.
SEC Form 4: A required filing disclosing insider transactions in a public company’s securities.
Direct holdings: Shares owned personally by an individual, not through trusts or other entities.
Indirect exposure: Ownership or economic interest in shares held via trusts, family members, or other entities.
Derivative activity: Transactions involving financial contracts whose value is based on an underlying asset, such as options or warrants.
Trust attribution: Assigning ownership of shares to an individual through a trust or similar legal arrangement.
Weighted average purchase price: The average price paid per share, calculated by weighting each purchase price by the number of shares bought or sold.
Clinical-stage: Refers to a company or product currently undergoing human clinical trials but not yet approved for commercial sale.
Conjugation: A vaccine technology that links a protein to a polysaccharide to enhance immune response.
Antibiotic resistance: The ability of bacteria to withstand the effects of antibiotics, making infections harder to treat.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
TTM: The 12-month period ending with the most recent quarterly report.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 966%* — a market-crushing outperformance compared to 194% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of January 3, 2026.
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte's Chief Technical Ops Officer Sells Shares

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the T. Rowe Price Capital Appreciation Equity ETF (Symbol: TCAF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.05 per unit.
With TCAF trading at a recent price near $38.11 per unit, that means that analysts see 18.20% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of TCAF's underlying holdings with notable upside to their analyst target prices are Vaxcyte Inc (Symbol: PCVX), Workday Inc (Symbol: WDAY), and Danaher Corp (Symbol: DHR). Although PCVX has traded at a recent price of $41.65/share, the average analyst target is 135.29% higher at $98.00/share. Similarly, WDAY has 25.26% upside from the recent share price of $225.17 if the average analyst target price of $282.06/share is reached, and analysts on average are expecting DHR to reach a target price of $251.68/share, which is 19.88% above the recent price of $209.94. Below is a twelve month price history chart comparing the stock performance of PCVX, WDAY, and DHR:
Below is a summary table of the current analyst target prices discussed above:
Name
Symbol
Recent Price
Avg. Analyst 12-Mo. Target
% Upside to Target
T. Rowe Price Capital Appreciation Equity ETF
TCAF
$38.11
$45.05
18.20%
Vaxcyte Inc
PCVX
$41.65
$98.00
135.29%
Workday Inc
WDAY
$225.17
$282.06
25.26%
Danaher Corp
DHR
$209.94
$251.68
19.88%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 21.49
P/B	2.70 2.57
P/FCF	0.00 18.61

Indicator	TTM Median
ROE	0.00 19.43
ROA	0.00 6.99
Net Worth	8.11 0.21
Quick Ratio	0.00 1.79
Current Ratio	7.49 2.79

Indicator	TTM Median
EPS	-1.80 0.43
EPS Forecast	-1.46 0.37
Revenue	0.00 17.00M
Gross Profit	0.00 —
EBITDA	-159.00M —

Vaxcyte, Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue